CD200-CD200R轴与疾病的相关性及其研究进展  

Correlation of CD200-CD200R axis and diseases and its research progress

作　　者：徐晗 毕宇鑫 李桂霞 李剑 王琉丽 郝瑞家 郑学敏 黄瑞晶 韩进 李飞[1] 王根辈 XU Han;BI Yu-xin;LI Gui-xia;LI Jian;WANG Liu-li;HAO Rui-jia;ZHENG Xue-min;HUANG Rui-jing;HAN Jin;LI Fei;WANG Gen-bei(China Pharmaceutical University,Nanjing 211198,China;TASLY Pharmaceutical Group Co.,Ltd.,Tianjin 300000,China)

机构地区：[1]中国药科大学,江苏南京211198 [2]天士力医药集团股份有限公司,天津300000

出　　处：《药学学报》2024年第4期822-830,共9页Acta Pharmaceutica Sinica

摘　　要：CD200及其受体CD200R构成一种内源性抑制信号,CD200与CD200R的结合能够调节对致病刺激的免疫反应,近年来备受研究人员广泛关注。研究发现CD200-CD200R轴参与包括自身免疫性疾病、心脑血管疾病、感染和肿瘤等多种病理炎症的调控,该轴被认为是多种疾病潜在的治疗靶点。本文从CD200和CD200R的蛋白结构、分布表达、生物学功能以及与疾病的相关性进行了系统阐述,并对其作为药物靶标开发的研发现状和研发思路进行分析,以期为基于该靶点的新药研发提供理论支持。CD200 and its receptor CD200R constitute an endogenous inhibitory signal.The binding of CD200 and CD200R can regulate the immune response to pathogenic stimuli,which has received much attention in recent years.It has been found that CD200-CD200R is involved in the regulation of many kinds of pathological inflammation,including autoimmune diseases,cardiac cerebrovascular disease,infection and tumor.This paper reviews the protein structure,distribution,expression,biological function of CD200-CD200R and the correlation with diseases,and analyses the current status and development ideas of CD200-CD200R as drug targets.It aims to provide theoretical support for new drug research and development based on this target.

关 键 词：CD200 CD200R 疾病 靶向药物 免疫检查点 

分 类 号：R966[医药卫生—药理学]